Baird served as co-manager on this offering
AboutNatera, Inc. (“Natera” or the “Company”) (NASDAQ:NTRA) recently completed an underwritten public offering of 6,052,631 shares of its common stock at a price to the public of $19.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 789,473 shares of common stock. Net proceeds to Natera from the offering were approximately $107.5 million after deducting underwriting discounts and the estimated expenses of the offering. Natera intends to use the net proceeds from this offering for working capital and general corporate purposes and continued investments in research and development for its core technology and development of its product offerings.
Natera is a global leader in cell-free DNA testing. The mission of the Company is to change the management of disease worldwide. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California. The Company offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer including bio pharmaceutical companies, and genetic laboratories through its cloud-based software platform. Natera is headquartered in San Carlos, California.
CONTACT US TO LEARN MORE
- April 2019
- Natera, Inc.
- Target Location
- North America